Takeda making case for SC form of Entyvio

Entyvio (vedolizumab), Takeda’s (TYO: 4502) gut-selective biologic that is approved as an intravenous (IV) formulation for ulcerative colitis (UC) and Crohn’s disease (CD), could soon become available in subcutaneous (SC) form.

This comes after Takeda presented Phase III data from the Phase III VISIBLE 1 trial at the 2018 United European Gastroenterology (UEG) Week congress in Vienna, which showed the effectiveness of the SC form for maintenance therapy in adults with moderately to severely active UC who achieved clinical response at week 6 following two doses of open-label Entyvio IV therapy.

At week 52, a statistically-significant proportion of patients receiving Entyvio SC achieved clinical remission compared to patients receiving placebo.